BACKGROUND: Heat shock protein 27 (hsp-27) is overexpressed in approximately 67% pure ductal carcinoma in situ (DCIS), in approximately 50% DCIS associated with invasive ductal carcinoma (IDC), and in approximately 25% IDC alone. If this decrease in hsp-27 expression has a role in the progression of malignancy in IDC, we postulate a further reduction in expression in nodal metastasis. METHODS: To test this hypothesis, we evaluated the distribution of hsp-27 in primary IDC and in synchronous regional lymph node metastasis within the same patient by immuno-histochemistry. RESULTS: Nine of 30 primary IDCs (30%) and 22 of 30 lymph node metastases (73%) overexpressed hsp-27. Contrary to our hypothesis, of 21 IDCs with no or low hsp-27 expression, 13 (62%) had overexpression of this protein within nodal metastasis. CONCLUSIONS: hsp-27 appears to confer cytoprotection for metastatic cells, which may help explain why hsp-27 overexpression is associated with reduced disease-free survival in breast carcinomas.
BACKGROUND:Heat shock protein 27 (hsp-27) is overexpressed in approximately 67% pure ductal carcinoma in situ (DCIS), in approximately 50% DCIS associated with invasive ductal carcinoma (IDC), and in approximately 25% IDC alone. If this decrease in hsp-27 expression has a role in the progression of malignancy in IDC, we postulate a further reduction in expression in nodal metastasis. METHODS: To test this hypothesis, we evaluated the distribution of hsp-27 in primary IDC and in synchronous regional lymph node metastasis within the same patient by immuno-histochemistry. RESULTS: Nine of 30 primary IDCs (30%) and 22 of 30 lymph node metastases (73%) overexpressed hsp-27. Contrary to our hypothesis, of 21 IDCs with no or low hsp-27 expression, 13 (62%) had overexpression of this protein within nodal metastasis. CONCLUSIONS:hsp-27 appears to confer cytoprotection for metastatic cells, which may help explain why hsp-27 overexpression is associated with reduced disease-free survival in breast carcinomas.
Authors: D C Allred; G M Clark; R Molina; A K Tandon; S J Schnitt; K W Gilchrist; C K Osborne; D C Tormey; W L McGuire Journal: Hum Pathol Date: 1992-09 Impact factor: 3.466
Authors: A Thor; C Benz; D Moore; E Goldman; S Edgerton; J Landry; L Schwartz; B Mayall; E Hickey; L A Weber Journal: J Natl Cancer Inst Date: 1991-02-06 Impact factor: 13.506
Authors: Sophie Vasseur; Albrecht Hoffmeister; Stephane Garcia; Claude Bagnis; Jean-Charles Dagorn; Juan Lucio Iovanna Journal: EMBO Rep Date: 2002-01-29 Impact factor: 8.807
Authors: Ganachari M Nagaraja; Punit Kaur; William Neumann; Edwina E Asea; María A Bausero; Gabriele Multhoff; Alexzander Asea Journal: Cancer Prev Res (Phila) Date: 2011-12-20
Authors: Zhenkun Zhu; Xin Xu; Yanke Yu; Martin Graham; Mark E Prince; Thomas E Carey; Duxin Sun Journal: Mol Pharm Date: 2010-08-02 Impact factor: 4.939
Authors: María Fernanda García; Salomé González-Reyes; Luis Ovidio González; Sara Junquera; Nana Berdize; José Manuel Del Casar; María Medina; Francisco José Vizoso Journal: Int J Exp Pathol Date: 2010-04-20 Impact factor: 1.925